developing Game-Changing molecular imaging technologies

Through its two wholly owned subsidiaries, Serac Life Sciences is developing two late-stage molecular imaging technologies to help physicians deliver personalised medicine to more patients.  

developing Game-Changing molecular imaging technologies

Through its two wholly owned subsidiaries, Serac Life Sciences is developing two late-stage molecular imaging technologies to help physicians deliver personalised medicine to more patients.  

Our goal is to bring better care & quality of life to patients wherever they are

Images Courtesy of Prof C Becker, University of Oxford

99mTc-maraciclatide - A novel imaging agent under investigation for endometriosis and inflammatory arthritis

Serac Healthcare is a clinical radiopharmaceutical company with deep expertise in discovering, developing and commercialising innovative molecular imaging technologies. Its goal is to bring to market effective tools to accelerate diagnosis and to deliver earlier and more effective treatment decisions for patients.

Its radio-labelled imaging agent, 99mTc-maraciclatide, is being developed to underpin personalised medicine primarily in the fields of endometriosis and inflammatory arthritis.

99mTc-maraciclatide binds to the αvβ3 integrin which is crucial to the development of new blood vessels, a key feature of both conditions.

Clinical trials with world-leading academic partners are underway in both these indications.

99mTc-maraciclatide is for investigational use only and is not approved by the FDA or UK and European regulatory authorities.

Seracam® - A revolutionary high resolution hybrid gamma-optical camera for point-of-care imaging

Serac Imaging Systems is a medtech company and developer of Seracam.

Seracam incorporates cutting-edge technology into a miniaturised, cost-effective, high resolution gamma camera with real time optical video image fusion. It has been designed as a highly versatile and compact alternative to traditional fixed nuclear medicine cameras, to enable molecular imaging procedures at the patient bedside, and also improve workflow in the nuclear medicine department.

Seracam is currently being evaluated in a number of clinical settings.

Seracam is for investigational use only and has not been registered or approved by the FDA, UK, European or Malaysian regulatory authorities.

190m Women worldwide affected by endometriosis
0 m
18m People worldwide live with rheumatoid arthritis
0 m
35 + Standard nuclear medicine procedures
0 +
9 yrs Average time to diagnose endometriosis
0 yrs
$19.3bn Cost/yr of rheumatoid arthritis to the US economy
$ 0 bn
10,000 Nuclear medicine facilities worldwide
0

Investment Opportunities

Serac Life Sciences is a privately owned holding company for Serac Healthcare Ltd and Serac Imaging Systems Ltd. We are always ready to talk to investors who match our ambitions and can help us excel. If you would like to discuss investment opportunities, please do get in touch.

Our Board

Discover more about the team behind Serac Life Sciences

David Hail

Chairman

Over 30 years’ experience within and consulting to the pharmaceutical, healthcare and molecular imaging industries at Senior Executive and Board level.

Read more

Paul Cload, PhD

Director

Over 30 years’ experience in the pharmaceutical, medical device and diagnostics industries having held senior, global positions in clinical development and strategic/tactical marketing with the Wellcome Research Laboratories, Amersham Health, GE Healthcare and a medical imaging start-up.

Read more

James McCutcheon, FCCA

Director

James is a highly experienced commercial and finance director with over 30 years’ experience in the pharmaceutical and medical device sectors, having held senior finance positions in both large multinationals, as well as smaller fast growing SMEs.

Read more

Mark Rosser, PhD

Director

Mark has been working on the development of products for nuclear medicine since 1994, with experiences covering manufacturing and supply through clinical development and regulatory submissions. A co-founder of Serac Imaging Systems and Serac Healthcare, Mark has been CEO of Serac Imaging Systems since 2021.

Read more

Latest News

150-Patient Clinical Study of Seracam® Portable Hybrid Gamma-Optical Camera Presented at EANM’26

Serac Imaging Systems Limited  and its clinical investigators from the Faculty of Medicine at Universiti Malaya, Malaysia, announce that an e-poster reporting a completed 150-patient clinical study of Seracam® in routine nuclear medicine practice at the Universiti Malaya Medical Centre is being presented at the European Association of Nuclear Medicine (EANM) Annual Congress. The congress is taking place from 17th to 21st October 2026 at the Austria Center Vienna, Austria.

Seracam® Gamma-Optical Camera for Real-Time Radiation Imaging Presented at FS Radiation Protection Conference in Winterthur, Switzerland

Serac Imaging Systems Limited, developer of Seracam® a portable hybrid gamma-optical camera for real-time radiation imaging, is presenting a poster at the 57th annual conference of the Fachverband für Strahlenschutz (FS), the German-Swiss Association for Radiation Protection, which this year marks 60 years of radiation protection. The conference is taking place in Winterthur, Switzerland from 28th September to 2nd October.

First Commercial Installation of Seracam® at Sellafield

Serac Imaging Systems Limited announces the sale of a system to Sellafield, the UK's largest nuclear site and one of the most complex decommissioning programmes in the world. The deployment marks Seracam's first commercial installation at a major nuclear facility and will support Sellafield Ltd's ongoing programme of radiological characterisation across legacy facilities scheduled for decommissioning.